So, realistically, 2026 is the earliest we might see retatrutide on the market for general use
however, this remains hypothetical at present
Research in rodent models suggests that allulose may increase GLP-1 secretion, possibly through effects on intestinal glucose transporters or direct stimulation of enteroendocrine cells
Encourages healthy collagen production*
No matter what option you choose, you should explore these options with healthcare providers: this is essential to determine the most effective course of action
Preclinical studies demonstrated that GLP-1 receptor agonists increased bone formation and reduced bone resorption in metabolic bone disease models, including diabetic osteoporosis, postmenopausal osteoporosis, and glucocorticoid-induced osteoporosis